alexa The Use of H2-Blockers in Intensive Care | OMICS International
ISSN: 2167-065X
Clinical Pharmacology & Biopharmaceutics
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

The Use of H2-Blockers in Intensive Care

Kaur P*, Mukherjee A, Rutkevich AS, Rutkevich EU, Predkо VA and Gerasimchik PA

Department of Medicine, Grodno State Medical University, Grodno, USA

*Corresponding Author:
Prabhjot Kaur
Department of Medicine, Grodno State Medical University
Grodno, USA
Tel: +375-152-435561
E-mail: [email protected]

Received date: August 21, 2017; Accepted date: August 29, 2017; Published date: August 31, 2017

Citation: Kaur P, Mukherjee A, Rutkevich AS, Rutkevich EU, Predko VA, et al. (2017) The Use of H2-Blockers in Intensive Care. Clin Pharmacol Biopharm 6:176. doi: 10.4172/2167-065X.1000176

Copyright: © 2017 Kaur P, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Clinical Pharmacology & Biopharmaceutics

Abstract

Treatment plan for a patient in ICU is quite complicated as doctors from different specialities take part in it with advanced methods and machines. But the intensive treatment and diseases of the patient also has complications in itself.

Keywords

Proton pump inhibitors; H2-blockers; ICU; Stress ulcers; Intensive therapy

Introduction

Treatment process in the critical care unit is quite complicated. When a patient is in critical condition, gastro-intestinal tract is often affected in the first place. Conditions like severe burn injury, severe traumas (orthopaedic trauma) sepsis, bacteraemia, acute pancreatitis, patients with pre-existing gastritis or stomach ulcers are highly susceptible to intestinal bleeding caused by stress ulcers. Internal bleeding from the ulcer, contributes a lot to worsen the condition of the patient. In such cases, pharmacological prophylaxis is one of the most effective ways to overcome the situation. Proton pump inhibitors and H2 receptor blockers are widely used for this purpose. As it is known, each group of drug has its own side effects and contraindications. Superiority of one group of drugs over another group is not documented with proof. Recommended usage of drug should be based on some factors. Such as: condition and probable side effects on a partial patient due to the use of the particular drug, availability and financial benefit for the particular hospital. Taken in account all the above mentioned points, H2 receptor blockers can be recommended for the prophylaxis of stress ulcers. Of which, the most popular drugs are Ranitidine and Famotidine.

Treatment plan for a patient in ICU is quite complicated as doctors from different specialities take part in it with advanced methods and machines. But the intensive treatment and diseases of the patient also has complications in itself.

GIT gets effected first line in critically ill patients. The pathological studies behind this are still under research. As a whole, pathology under this can be explained by the vasoconstriction due to the ischemia of the gastric mucosa, which gives path for formation of gastric ulcers. Erosive ulcers of stomach and duodenum are noted as high as 75% (40-100%) in patients after the first hour of admission in ICU. The factors which are connected to stress ulcers are as follows [1]:

Very high risk factors:

1. Artificial Ventilation (>48 h)

2. Coagulopathies

3. Thrombocytes <50 000

4. INR>1, 5

5. АPTT (R)>2, 0

6. Burn surface area>30%

A. Shock

B. Severe sepsis

C. Severe Trauma

D. Cerebral and Spinal trauma

E. Renal Insufficiency

F. Steroidal Therapy

Gastrointestinal track bleeding directly increases the duration of the treatment and complicates the process. It increases artificial ventilation time, demands blood transfusion, prolongs the time of stay in ICU thereby decreasing hospital-bed capacity and increases the risk of lethal outcome. The average stay for such patients in ICU is 8 days on an average and also a 4-fold increased mortality rate is noted [2]. Of course it should be mentioned that a steep downfall of death -rate in such patients is seen in last decade. In 1970 the rate varied between 5.5-33% [3], whereas in 2010 it is <5%. Most probably this is due to prophylactic use of pharmaceutical drugs, pulmoprotective lung ventilation and modern methods of hypo and hypovolemic control.

For all the patients in ICU having one or more risk factors for GIT bleeding, pharmaceutical prophylaxis is must. For this purpose Proton pump Inhibitors and H2 receptor blockers are used extensively.

There are a lot of research works, publications and discussion regarding the use of Proton pump Inhibitors and H2 receptor blockers. But most of them fail to indicate superior group. Both have nearly same effects over hospitalisation period and end results. However the use of group of drugs must be based upon the particular case of the patient, possible co action, adverse reaction, availability and economic benefit for the patient care.

The fact should be taken under consideration that, prophylaxis of stress ulcers routinely can cause serious side-effects and complications. Near about 70% of the patients without risk factors are treated for stress ulcers, during and even after the ICU setting [4].

Decreased acidity of gastric juice decreases the natural barrier function from intestinal infections. This can result in inoculation with Nosocomial Pneumonia, infections by Clostridium difficille.

The Miano TA et al. showed that use of Proton pump Inhibitors is associated with increased risk of Hospital Acquired Pneumonia (HAP), especially in ICU setting, whereas use of H2 receptor blockers didn’t increase the risk of (HAP) [5,6].

The research work conducted by Вeaulieu, Kwok and colleague refers to the increased risk of clostridia infection [7,8] with the use of Proton Pump Inhibitors.

According to the Publication in “Pharmacotherapy” H2 receptor blockers are cheaper than the other, thus treatment expenses becomes less, it increases chances of survival and escapes adverse effects [9].

Drugs decreasing the acidity of the gastric juice have some side effects, as other drugs.

Proton pump inhibitors present themselves with pharmacological reactions with other drugs, hypomagnesaemia, increased risk for infections, acute interstitial nephritis, increased risk of fractures, risk of iron deficiency and vit-B12 deficiency.

H2 receptor blockers have the following effects: increased tolerance with time, it does not interfere with cytochrome P450 system, thrombocytopenia, arrhythmia (bolus i/v dose). Some drugs also have Specific reactions with cimetidine.

Ranitidine and Famotidine are the popular drugs from H2 receptor blockers. Both of them are available as intravenous form, and are widely used in ICU setting. It is well known that treatment in ICU is a long, complex and expensive process. It is important to take care of pharmaceutical budget. It’s very important to understand that price is just a mere factor. All the positive and negative sides should be understood well in order to prescribe a particular drug in order of betterment both the patient and the budget.

Justification of use of famotidine over ranitidine

1. Famotidine suppress basal gastric secretion by 40-150 times than that of cimetidine and 7-20 times of that of Ranitidine, which gives the same effect keeping the pH high. Famotidine binds with Histamine receptors thus providing a long lasting effect. In equimolar doses Famotidine gives 1.3 times more effect than any other H2 receptor blocker.

2. Serious side effects on cardiovascular system, central nervous system, endocrine and renal system from the use of Famotidine is not documented. Most importantly Famotidine very rarely causes hallucinations, delirium and changes in orientation. As we all know any kind of deterioration in CNS in ICU setting is dangerous for the patient.

3. Famotidine do not go through cytochrome P450 system, which is very important for clinical practice, where patients receive a number of drugs on a daily basis. Drugs like warfarin, theophylline and others don’t get interfered.

4. Cimetidine and Ranitidine decrease the activity of alcohol dehydrogenase, but famotidine do not interfere with Alcohol Dehydrogenase. Thus it can be used in patients with alcoholism, or in patients who take alcohol. (In Republic of Belarus, population above 15 years of age consume 17.5 litters of pure alcohol per person per year [10]).

5. Famotidine is injected twice a day, and Ranitidine 3-4 times a day. The number of times of contact with intravenous catheter is directly proportional to catheter related infections. Also number of sterile gloves usage, syringes decreases if number of dosage decreases. Thus making the treatment a little more economical.

6. On injection of bolus dose of Ranitidine hypotension, bradycardia, arrhythmia and asystolia can occur. But dosage of Famotidine in course of 2 minutes is safe for cardiovascular system. This is very important for high risk cardiac patients, for patients with unstable blood pressure, and for emergency surgeries [11].

From the above studies we see that use of H2 receptor blockers is more suitable in critically ill patients. Again, use of Famotidine for the treatment is economic, comparatively with fewer side effects and improved Post ICU results are recommended.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 236
  • [From(publication date):
    September-2017 - Dec 18, 2017]
  • Breakdown by view type
  • HTML page views : 199
  • PDF downloads : 37
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version